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Abstract: The biology of both normal and tumor development clearly possesses overlapping and 
parallel features. Oncogenes and tumor suppressors are relevant not only in tumor biology, but 
also in physiological developmental regulators of growth and differentiation. Conversely, genes 
identifi ed as regulators of developmental biology are relevant to tumor biology. This is particularly 
relevant in the context of brain tumors, where recent evidence is mounting that the origin of 
brain tumors, specifi cally gliomas, may represent dysfunctional developmental neurobiology. 
Neural stem cells are increasingly being investigated as the cell type that originally undergoes 
malignant transformation – the cell of origin – and the evidence for this is discussed.
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Origin of brain tumors: historical insights
Over a century ago, the German pathologist Julius Cohnheim described the similarities 
between tumors and embryonic cells and suggested that “embryonic rests” were the 
source of tumors (Rather 1978). Later, the primitive cytoarchitecture and embryonic 
features of many malignant brain tumors was also described by Bailey and Cushing 
(1926). Smyth and Stern’s (1938) observed that “subependymal glia may actually be 
the point of origin of tumors of the thalamus.”
These earlier descriptions were further advanced in 1944, Joseph Globus and 
Hartwig Kuhlenbeck called attention to the subependymal cell plate in the adult brain 
and described this structure as one with primitive cellular composition. Based on a study 
with human brain tumors, they stated that “one of the most important sources for such 
immature embryonal residue from which neuroectodermal tumors are likely to develop 
under certain still unknown conditions is the subependymal plate.” (Globus 1944).
The subependymal plate was better characterized as a “mitotically active and well 
defi ned subependymal layer is present in mammalian brains throughout life” and 
Lewis (1968) suggested that they could be a “possible source of different histological 
varieties of glioma, in particular those tumors in paraventricular situation and butterfl y 
gliomas of the corpus callosum.”
In the late 1960s Hopewell and Wright (1969) demonstrated increased glial tumors 
with periventricular implantation of carcinogens in rats. In the 1970s, periventricular 
tumors were then demonstrated to occur in the subventricular region after intraventricular 
inoculation with avian sarcoma viruses, with a much higher rate of tumors occurring 
in neonatal rats versus adult rats (Copeland et al 1975; Copeland and Bigner 1977; 
Vick et al 1977). A single dose of ethylnitrosurea administration to pregnant rats also 
induced periventricular tumors in the offspring (Koestner et al 1971).
Now clear evidence exists for the “subependymal plate, as described by Gobus 
and Kuhlenbeck is the subventricular zone (SVZ), know to be the largest cellular 
region of neural stem cells (NSCs) in the adult mammalian brain. The NSCs have 
been characterized by Buyalla and provide the migratory neuroblasts for neurogeneis 
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in the olfactory bulb in rodents (Figure 1) (Sanai et al 2005). 
Recently, this migratory path for SVZ NSCs was also 
described in humans (Curtis et al 2007).
Reappraising the prevailing theory 
of tumor genesis
It has been widely accepted that cancer occurs as a 
consequence of genetic and epigenetic alterations 
in a differentiated cell. These alterations could provide 
a proliferative advantage and ultimately lead to uncontrolled 
growth and spread of the malignant cells. This theory 
suggests that tumors, such as gliomas, result from mutations 
to terminally differentiated astrocytes and oligodendrocytes 
that “de-differentiate” into a less differentiated phenotype 
(Mabon et al 1950; Doetsch et al 1999; Sakariassen 
et al 2007). Although the neoplastic transformation of 
fully differentiated glia is widely assumed to be the 
mechanism of gliomagenesis, this hypothesis has never 
been adequately tested.
Evidence for NSC as the cell of origin
The neurogenic zones within the human central nervous 
system (CNS) with their resident NSCs are considered the 
leading candidates for transformation leading to brain tumors. 
Specifi cally mitotically active cells (NSCs and their direct 
progeny, transit amplifying cells) are the cells that have the 
greatest probability of being the brain tumor cell of origin.
NSCs and gliomas share histological 
and biological similarities
Gliomas have long been described by pathologists for their 
remarkable cellular heterogeneity, and in fact the most 
aggressive and malignant glioma (glioblastoma multiforme) 
was termed based partly on the histological diversity 
comprising this tumor, hence “multiform.” A transformed 
NSC could provide this cellular landscape due to their 
mulitipotentiallity (ability to differentiate into the cell 
types that constitute their respective germ line). Mixed cell 
gliomas exist, such as oligoastrocytomas, and have both 
oligodendrocytes and astrocytes (Valtz et al 1991) and 
could be independent transformation of two differentiated 
cells, as suggested by the dedifferentiation theory of tumor 
genesis. More plausible would be the transformation of a 
single, bipotential progenitor cell such as a NSC or a transit 
amplifying cell (Chekenya and Pilkington 2002). These 
mixed cell gliomas also exhibit loss of heterozygosity 
on chromosomes 1p and 19q in both the astrocytic and 
oligodendrocytic components (Kraus et al 1995), suggesting 
that, in oligoastrocytomas, the astrocytes and oligodendrocytes 
comprising the tumor have a shared cell of origin.
Further, many glioma cells are undifferentiated, and 
lack expression of differentiated cell markers, as well 
as demonstrate staining with markers for nestin. Nestin 
expression is one hallmark feature of NSCs (Dahlstrand 
et al 1992; Tohyama et al 1992), and has become a reliable 
marker of NSCs (Lendahl et al 1990). Gliomas and NSCs 
also exhibit characteristic overlapping behavior (Table 1) 
(Sanai et al 2005), such as high motility, association with 
vasculature and white matter tracts (Shoshan et al 1999; 
Doetsch et al 2002; Palmer et al 2000).
NSCs more likely to accumulate 
oncogenic mutations
Accumulation of oncogenic genetic hits by cells is an infrequent 
stochastic event that most likely takes considerable time to 
result in transformation. NSCs, defi ned by their ability to self 
renew are both mitotically active and exist during the lifetime 
Figure 1 The cells of the subventricular zone, labeled with the astrocyte marker 
GFAP (shown in green), line the lateral walls of the lateral ventricles. This is the 
largest known region of adult neural stem cells in the human brain; it is composed 
of the deep subcortical white matter A), a periventricular ribbon of astrocytes that 
can function as neural stem cells B), a dense layer of astrocytic processes C), and the 
ependymal lining D). Throughout adult life, astrocytes from the subventricular zone 
exhibit a unique capacity for multipotency and self-renewal in vitro. Copyright © 2005. 
Reproduced with permission from Sanai N, Alvarez-Buylla A, Berger M. 2005. Neural 
stem cells and the origin of gliomas. N Engl J Med, 353:811–22.
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of the animal, allowing them to potentially accumulate the 
necessary multiple mutations for tumor formation. Accord-
ingly, the cellular origin of gliomas would most likely occur 
from the proliferative zones in the mammalian CNS such as the 
SVZ contain at least two types of mitotically active cells: NSCs 
and transit amplifying cells (TACs) (Seri et al 2004). Although 
TACs exist only briefl y and then differentiate, their total cel-
lular compartment is signifi cantly larger than NSCs and total 
number of global number of divisions during their relatively 
short lifespan are comparable to NSCs that exist throughout life 
yet are less mitotically active (Figure 2) (Vescovi et al 2006).
Cancer stem cells
Approximately 150 years ago, pathologists Rudolph 
Virchow and Julius Cohnheim suggested there were 
histological similarities between the developing fetus and 
certain cancers (such as teratocarcinomas) and that both tis-
sues have the capacity to differentiate and proliferate. This 
“embryonal-rest hypothesis” is the historical version of today’s 
cancer stem cell (CSC) hypothesis (Huntly and Gilliland 2005). 
As defi ned at the American Association for Cancer Research 
workshop on cancer stem cells: cancer stem cells are cells that 
(1) self renew and (2) re-supply the tumor with the various 
lineages of cells of which it is comprised. Self renewal can only 
be defi ned experimentally by the ability to recapitulate the 
generation of a continuously growing tumor or tumor initiation 
cell (Figure 3) (Clarke et al 2006; Lee and Herlyn 2007).
The original work establishing the CSC model was based 
on the hematopoietic system. Evidence for leukemia-CSCs 
was fi rst reported in 1994 when Lapidot and colleagues 
isolated a rare population of CD34+CD38− cells from 
patients with acute myeloid leukemia. Infusion of these 
CD34+CD38− cells into severe combined immune-defi cient 
mice resulted in leukemic blast generation; however, more 
differentiated cells (CD34+ CD38+) did not generate 
leukemia (Lapidot et al 1994; Al-Hajj et al 2003; Buzzeo 
et al 2007). On a molecular level, CSCs share properties 
with normal stem cells. They have similar markers and 
signaling pathways, respond to environmental cues, as well 
as telomerase activity, apoptosis clearance and increased 
membrane transporter activity (Sakariassen et al 2007).
The fi rst report of cells with stem-like properties in brain 
tumors was by Ignatova and colleagues (2002) where surgical 
specimens of glioblastoma multiforme were shown to have 
Table 1 Characteristics intrinsic to neural stem cells and gliomas. 
Copyright © 2005. Reproduced with permission from Sanai N, 
Alvarez-Buylla A, Berger M. 2005. Neural stem cells and the origin 
of gliomas. N Engl J Med, 353:811–22
High motility
Diversity of progeny
Robust proliferative potential
Association with blood vessels
Association with white-matter tracts
Immature expression profi les
 Nestin expression
 EGF-receptor expression
 PTEN expression
 Hedgehog pathway activity
 Telomerase activity
 Wnt pathway activity
Abbreviation: EGF, epidermal growth factor.
A
B
C
Figure 2 Hierarchical organization of the functional compartments in renewing 
tissues A) The stem-cell compartment (purple), early transiently dividing progenitor 
compartment (orange), late transiently dividing progenitor compartment (red) and 
differentiated-cell compartment (green) are schematically described. Cells in the 
stem-cell and transiently dividing progenitor compartments could be the target of 
the onco-transformation that leads to the formation of tumour stem cells B) The 
neural precursors that make up similar functional compartments in the neurogenetic 
regions of the adult brain and that might be the source of brain tumour stem cells 
C) The structure of the subventricular zone, showing how these precursors fi t and 
are organized in the germinal neuroepithelium of the largest neurogenetic region of 
the adult brain.
Abbreviations: GABA, γ-aminobutyric acid; GFAP, glial fi brillary acid protein; HSA, 
heat-stable antigen; MAP2, microtubule-associated protein 2; NCAM1, neural cell 
adhesion molecule 1; PSA, polysialic acid; RMS, rostral migratory stream.
Stem Cells and Cloning:  Advances and Applications 2008:144
Ho et al
Figure 3 Overview of tumor stem cells in cancer. Cancer stem cells (tumor-initiating 
cells) divide asymmetrically, resulting in self-renewal of the tumor-initiating cell and 
production of a daughter cell known as a transient-amplifying cell (progenitor cell). 
The transient- amplifying cell is not thought to possess self-renewing capabilities, but 
instead divides indefi nitely to contribute to cancer progression. Copyright © 2007. 
Reproduced with permission from Lee J, Herlyn M. 2007. Old disease, new culprit: 
tumor stem cells in cancer. J Cell Physiol, 213:603–9.
clonogenic neurosphere-forming cells that expressed both 
neuronal and glial markers upon differentiation (Figure 4) 
(Ignatova et al 2002; Vescovi et al 2006). Subsequently, 
the Dirks group demonstrated CSC in brain tumors by 
1 transplantation of CD133+ or CD133− populations into 
immunodefi cient mice. With as few as 100 CD133+ cells 
from the primary tumor, a new phenocopy of the tumor 
could be created in the transplanted mice; and unsorted 
or CD133− primary tumor cells were unable to cause de 
novo tumor generation. As part of what has come to defi ne 
CSCs-self-renewal capacity – was also shown by confi rming 
the ability of serially transplanted CD133+ cells to recapitulate 
the original tumor (Singh et al 2004; Buzzeo et al 2007). These 
fi ndings established the presence of brain tumor stem cells 
(BTSCs), cells which can differentiate into the neural lineages, 
and exhibit self renewal as demonstrated by recapitulation 
of primary tumors with serial transplantation. This has been 
shown for other types of brain tumors as well (Merkle et al 
2004; Taylor et al 2005). The existence of these BTSCs adds 
further evidence toward the NSCs origin of gliomas by confi rm-
ing that different brain tumors contain transformed, undifferen-
tiated neural precursors that respond to the same mitogens that 
activate adult NSCs (Vescovi et al 2006). Second, they indicate 
that tumor stem-like cells possess some of the molecular fea-
tures of NSCs. Third, BTSCs, through asymmetric division, 
could generate a BTSCs and a progenitor cell, the latter of 
which may migrate away to either form or contribute to the 
tumor mass (Vescovi et al 2006, Berger et al 2004).
Gliomas and NSCs have common 
regulatory pathways
Neural stem cells and progenitor cells have activated cellular 
pathways, such as pro-mitotic genes, telomerase activity, 
and anti-apoptotic genes. This innate capacity overlaps with 
the mechanisms underlying tumor initiation, progression, or 
both. Thus, NSCs may require the least amount of mutations 
to become transformed.
1. EGFR expression is up-regulated in primary glioblastoma 
multiforme and transiently dividing progenitors (type C 
cells) (Mellinghoff et al 2005).
2. Fibroblast growth factors (FGFs) are involved in tumor 
proliferation and angiogenesis (Joy et al 1997; Auguste 
et al 2001) and also shown to regulate NSC proliferation 
and cell fate (Vescovi et al 1993; Gritti et al 1996; Palmer 
et al 1999).
3. Notch receptors and signaling is involved in NSC renewal 
(Hitoshi et al 2002; Shen et al 2004) and related to 
proliferative capacity of gliomas (Purow et al 2005).
4. PTEN is a tumor suppressor with an important function 
in the control of proliferation of neural stem cells and 
progenitor cells in vivo and in vitro (Baker and McKinnon 
2004; Groszer et al 2001; Reya and Clevers 2005). PTEN 
is inactivated in glioblastomas (Rasheed et al 1999; 
Wechsler-Reya and Scott 2001) and its preservation 
in glioblastoma multiforme is clinically favorable 
(Mellinghoff et al 2005).
5. The Wnt-catenin pathway regulates adult neurogenesis 
(Chenn and Walsh 2003; Lie et al 2005) modulating its 
activity may increase glioma cell growth (Roth et al 2000).
Recent experiments have also highlighted the increased 
ability of progenitor cells to be transformed versus dif-
ferentiated cell types. If epidermal growth factor receptor 
(EGFR) is transfected into transgenic Ink4a-Arf-/- mouse 
(lacking genes for cell-cycle arrest) neural stem cells, the 
cells lead to glioma formation (Bachoo et al 2002). This 
contrasted with similar manipulation of differentiated mouse 
astrocytes. Further, if the undifferentiated mouse astrocytes 
were transfected with platelet-derived growth factor (pdgf ) 
transgene and converted to a less differentiated state, they 
showed increased oncogenicity (Dai et al 2001; Bachoo et al 
2002; Uhrbom et al 2002).
Mouse models of gliomas for investigation 
of glioma origin
Mouse models of gliomas are available and offer a unique 
opportunity to investigate tumor origin. These models, 
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unlike glioma models in Drosophila and C. elegans, 
recapitulate the human pathology in terms of such character-
istic structures as pleomorphic nuclei, diffusely infi ltrative 
margins, secondary structures of Scherer, necrosis with 
pseudopalisading tumor cells, and microvascular prolifera-
tion. Xenograft models fail to phenocopy the classic histo-
pathological features and are not an option for elucidating 
developmental mechanisms. Ultimately, these models of 
spontaneous tumor development and progression allows 
for the potential identifi cation of novel mechanisms for 
tumorigenesis (Ding et al 2001).
Relevance of identifying the glioma
cell of origin
Brain tumor classifi cation with current histological criteria 
fails to accurately categorize patients as many patients with 
similar grade brain tumors have highly variable clinical 
outcomes. Clearly, this classifi cation is one that at a minimum 
Figure 4 Immunofl uorescence photomicrographs of representative MC-PL clones derived from different cortical glial tumor specimens (T1–T3, T6, and T7) processed for 
double (A, B, C, E, F) or single (B inset, D) labeling for different neural markers. The cells positive for the neuronal marker β-III tubulin are stained green (FITC), and the cells 
that expressed the astroglial marker GFAP are stained blue (AMCA). The arrowhead in F points out a cell that is not labeled for GFAP, but is immunopositive for β-III tubulin 
(arrowhead in G). The short arrow in F points out a cell that is immunolabeled for GFAP, but immunonegative for β-III tubulin (short arrow in G). The long arrow in F and G 
points out a cell that is labeled with both immunomarkers. Scale bars are 10 μm (F and G) and 100 μm (A–E). Copyright © 2002. Ignatova T, Kukekov V, Laywell E, et al. 2002. 
Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia, 39:193–206.
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needs molecular modifi ers. Defi ning the cell of origin, and 
confi rming whether NSCs are indeed the cell of origin would 
improve not only glioma classifi cations, but also detection 
and treatment. The differential antigenic and molecular 
attributes of NSCs responsible for tumorigenesis could be 
exploited to target malignant cells prior tumor progression 
to clinical presentation. Indeed, defi ning cell of origin could 
help expand the concept of chemoprevention: targeting cells 
in the pre-morbid state.
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